Sonderup M et al., 2023-06: Case report of cholestatic hepatitis with bile duct injury three weeks after starting ivermectin for COVID-19 prevention, treated with corticosteroids and resolved. It is the clearest published clinical case of ivermectin-attributed liver injury.
We discuss a patient who developed jaundice and a liver injury 3 weeks after initiating ivermectin for COVID prevention.
Sonderup M et al., 2023-06: Case report of cholestatic hepatitis with bile duct injury three weeks after starting ivermectin for COVID-19 prevention, treated with corticosteroids and resolved. It is the clearest published clinical case of ivermectin-attributed liver injury. C5 liver case. Study type: single case report; N=1; South Africa. Dose: not stated in the abstract captured (the patient took ivermectin for COVID prevention; dose sits in the full text). Comparator: none. Funder and declared conflicts: not in the PubMed record. Histology per the abstract: 'a pattern of injury that was both portal and lobular, with a bile ductulitis as well as marked cholesasis'; managed with low-dose corticosteroids and well a year later. Study type: case report.
